NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
MeiraGTx Holdings PLC MGTX
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$81.4M
▲ 144.6% vs FY2024
EPS · FY25
$-1.42
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-368.2%
Net margin · FY25
-140.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 81.4M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 140 cents on every revenue dollar this year.
Per share
USD -1.42
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-368.2%
Return on equity, FY2025
ROE
Operating margin-130.2%
Net margin-140.3%
Return on assets-44.4%
Each USD of equity lost 368 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+39.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+72.3%
+39.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2025
Change, 5 years+83.6%
Change, 10 years—
The share count grew 84% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 244.4M
total assets, end of FY2025
Total assetsUSD 244.4M
EquityUSD -5.8M
CashUSD 65.9M
Current ratio0.75×
Equity funds -2% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.1
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA $B
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
·
0.0
0.0
0.0
−0.0
0.0
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EPS, diluted $
−1.42
−2.12
−1.49
−2.87
−1.80
−1.54
−1.65
−4.47
−3.72
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−368.2
−143.5
−65.7
−85.5
−37.5
−27.0
−40.3
−491.9
·
Shares out B
0.08
0.08
0.06
0.05
0.04
0.04
0.04
0.03
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed